COVID-19 and Parkinsonism /

Detalles Bibliográficos
Clasificación:Libro Electrónico
Otros Autores: Chaudhuri, K. Ray (Editor ), Rodr�iquez-Violante, Mayela (Editor ), Antonni, Angelo (Editor ), Boura, Iro (Editor )
Formato: eBook
Idioma:Inglés
Publicado: Cambridge, MA : Academic Press, 2022.
Edición:First edition.
Colección:International review of neurobiology ; v. 165.
Temas:
Parkinson's disease.
COVID-19 (Disease)
COVID-19
Maladie de Parkinson.
COVID-19.
Parkinson's disease
Acceso en línea:Texto completo
Tabla de Contenidos:
  • Intro
  • Covid-19 and Parkinsonism
  • Copyright
  • Contents
  • Contributors
  • Chapter One: Parkinsonism associated with viral infection
  • 1. Introduction
  • 2. Epstein Barr virus
  • 3. Hepatitis viruses
  • 4. Human immunodeficiency virus
  • 5. Herpes virus
  • 6. Influenza/H1N1
  • 6.1. Encephalitis lethargica
  • 7. Coxsackie virus
  • 8. Flaviviruses
  • 9. COVID-19
  • 10. Conclusion
  • References
  • Chapter Two: Covid-19, nervous system pathology, and Parkinson�s disease: Bench to bedside
  • 1. Introduction
  • 2. SARS-CoV-2 receptors
  • 3. Neuroinflammation in post-mortem Covid-19 brain
  • 4. Little evidence of neuro-invasion in post-mortem Covid-19 cases
  • 5. SARS-CoV-2 and parkinsonism
  • 6. Peripheral pathways that may contribute to neuroinflammation
  • 6.1. Olfactory pathway
  • 6.2. Enteric pathways
  • 6.3. Vascular pathways
  • 6.4. Hypoxia and ischemia
  • 7. Conclusion
  • References
  • Chapter Three: Prevalence and outcomes of Covid-19 in Parkinson�s disease: Acute settings and hospital
  • 1. Introduction
  • 2. Why should PwP be more or less susceptible to Covid-19?
  • 3. Covid-19 prevalence in Parkinson�s disease
  • 4. Covid-19 outcomes in Parkinson�s disease
  • 4.1. Hospitalization
  • 4.2. Mortality
  • 5. Reported modulators of Covid-19 risk in Parkinson�s disease
  • 5.1. Canonical Covid-19 risk factors
  • 5.2. Vitamin D
  • 5.3. Age, disease severity and dementia
  • 5.4. Parkinson�s disease medications
  • 6. Conclusion
  • References
  • Chapter Four: Covid-19 and Parkinson�s disease: Acute clinical implications, long-COVID and post-COVID-19 parkinsonism
  • 1. Introduction
  • 2. The acute effects of SARS-CoV-2 infection in people with Parkinson�s disease
  • 2.1. Dopaminergic signaling during infections
  • 2.2. The role of stress
  • 3. Parkinson�s disease and Long-COVID
  • 4. Post-covid-19 cases of Parkinsonism
  • 5. Conclusions
  • References
  • Chapter Five: Smell deficits in COVID-19 and possible links with Parkinson�s disease
  • 1. Introduction
  • 2. Clinical features of COVID-19 olfactory impairment
  • 2.1. Individual variables influencing COVID-19 olfactory impairment
  • 2.2. SARS-CoV-2 variants and their relationship with olfactory impairment
  • 3. Neuropathology of COVID-19 olfactory impairment
  • 4. Olfactory impairment in COVID-19 and parkinsonism
  • References
  • Chapter Six: Spotlight on non-motor symptoms and Covid-19
  • 1. Introduction
  • 2. Depression
  • 3. Anxiety
  • 4. Cognitive impairment
  • 5. Psychosis
  • 6. Delirium
  • 7. Hyposmia
  • 8. Gastrointestinal dysfunction
  • 9. Dysautonomia
  • 10. Pain
  • 11. Fatigue
  • 12. Sleep impairment
  • 13. Conclusion
  • References
  • Chapter Seven: Treatment paradigms in Parkinson�s Disease and Covid-19
  • 1. Introduction
  • 2. Management of PwP according to Covid-19 severity
  • 3. Asymptomatic or mild Covid-19 infection
  • 3.1. Anti-parkinsonian treatment: Role in Covid-19

Ejemplares similares